This event is fully booked
Back by popular demand, the BioMelbourne Network BioBriefing – Navigating the Grantscape is returning on Tuesday 16th May.
Find out about the grants and non-dilutive funding opportunities that are available and how companies in the biotech, medtech and pharma sector can access them.
Hear from representatives from Clarity Pharmaceuticals and Bio-Gene on their strategic approach to non-dilutive funding, and from program managers on what they’re looking to fund, how and when to apply.
Attendees will find out which support programs are available and how they can be leveraged to advance R&D pipelines and business objectives.
Date: Tuesday 16th May 2017
Time: Registration from 3:45 for 4:00pm – 5:15pm session, followed by a networking
Where: KPMG, Level 36, Tower Two, Collins Square 727 Collins Street Melbourne
(Prices include GST)
To check if your organisation is a member, click here
Alun is a Director in KPMG’s Government Incentives practice in Melbourne. He has over 20 years’ experience in assisting clients access government support for innovation and R&D activities and has worked closely with many biotech, medtech and pharmaceutical companies over that time.Alun is a member of KPMG’s national Health & Life Sciences practice and has a Master’s Degree in Physics from the University of Melbourne.
As a member of the BioMelbourne Network Board, Alun plays a key role in supporting the executive team respond to government’s formulation of new research funding policy and review of programs such as the R&D Tax Incentive.
Ms MacLeman has more than 25 years’ experience as a pharmaceutical, biotechnology and medical technology executive with roles in corporate, medical, commercial and business development at Schering-Plough Corporation (now Merck), Amgen, Bristol-Myers Squibb and Mesoblast Ltd.
Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the sector and is currently a non-executive director at Reproductive Health Sciences Ltd. and Oventus Medical Ltd.
Dr Matt Harris, PhD, MBA, Managing Director, Clarity Pharmaceuticals
Matt brings experience in biotechnology, pharmaceuticals, regulatory requirements, academic research and investment to Clarity. Matt has held leading managerial positions in Australian industry including CEO of Gateway Capital, an investment firm operating in the life science sector, CEO of an ASX listed medical device company and CEO of a start-up biopharmaceutical company. In addition, Matt has worked closely with government and regulatory agencies, as a former member of a drug evaluation committee within the Australian Therapeutics Goods Administration (TGA). Matt is currently the principal and co-founder of TM Ventures.
Matt McNamara, BioMedical Translation Fund, BioScience Managers
Matt is responsible for deal flow management and evaluation, leading all investment recommendations and due diligence. He has over 25 years experience in the healthcare & medical sciences sector. After initially being a Molecular Biology Research Assistant, Matt spent 11 years in Sales & Marketing, and General Management with Merck & Co. and Johnson and Johnson Medical Pty Ltd respectively. He has served as SVP Business Development for eBioinformatics Inc and was CEO of a Life Sciences Venture Capital fund, SciCapital Pty Ltd.
Matt founded BioBridge Australia, a biotechnology commercialisation Advisory company, in 2004 and advised a number of private and public biotechnology/investment companies. Matt joined BioScience Managers in 2005 and has been Chief Investment Officer since 2008.
Matt is currently a Director of: BioScience Managers Ltd; Avita Medical Ltd (ASX.AVH); Sea Dragon Ltd (NZX.SEA); SciCapital Pty Ltd; Rex Bionics Limited (NZ); Saluda Medical Pty Ltd.
Dr Carolyn O’Brien, Senior International Relations and Policy Officer, ATSE
Dr Carolyn O’Brien joined ATSE in October 2015 to lead its international engagement and strategy work. She brought to ATSE a wealth of experience in international relations and extensive international networks having worked in the International Office at Melbourne University for over ten years. Carolyn is currently part of the ATSE team working on the Global Connections Fund which connects researchers and SMEs, an element of the Government’s National Innovation and Science Agenda. Carolyn has a PhD in European Studies from Monash University.
Roger has recently been appointed as the CFO and Company Secretary of Bio-Gene Technology Limited. He has more than 20 years’ experience in senior finance roles in a wide variety of industries. His early career included working with a Chartered Accounting practice and two years with the Australian Taxation Office. Before Bio-Gene, Roger was CFO and Company Secretary for a number of SMEs both listed and unlisted including Patrys Limited, TPI Enterprises Ltd and eChoice Home Loans. In these roles he was responsible for all financial affairs and corporate administration as well as assisting in investor relations activities. He has over 15 years of biotechnology and pharmaceutical experience.
This event is kindly hosted by: